ArticleDiscover oncology2025
A prognostic model for head and neck squamous cell carcinoma based on radiotherapy sensitivity insights from nasopharyngeal carcinoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Single-Cell Transcriptomics Identifies Novel Prognostic Signatures in HNSCC Immunotherapy Response.Cancer science · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundRadioresistance significantly impairs treatment efficacy and prognostic outcomes in head and neck squamous cell carcinoma (HNSCC). This study aimed to identify radiotherapy sensitivity-related genes and construct a prognostic model for HNSCC, incorporating insights from nasopharyngeal carcinoma (NPC) as a related subtype.
methodsDifferentially expressed genes (DEGs) associated with radiotherapy response were identified using the GSE48501 dataset, primarily derived from NPC. Functional annotation was performed via Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses. Using the TCGA-HNSC dataset, we developed a prognostic risk model through univariate and LASSO-Cox regression analyses. The model was validated for prognostic accuracy and further analyzed for associations with immune cell infiltration, drug sensitivity, and survival outcomes using CIBERSORT, TIMER, Genomics of Drug Sensitivity in Cancer (GDSC), and nomogram analysis.
resultsWe identified 263 DEGs related to radiotherapy sensitivity and developed a robust prognostic model based on 8 hub genes. The model effectively stratified patients into high- and low-risk groups, with superior overall survival (OS) observed in the low-risk group. The Receiver Operating Characteristic (ROC) analysis confirmed high predictive accuracy for 1-, 3-, and 5-year OS. Immune infiltration analysis revealed reduced immune activity in the high-risk group, while drug sensitivity analysis highlighted potential therapeutic strategies. The nomogram further demonstrated excellent predictive performance.
conclusionThis study bridges insights from NPC-derived DEGs and HNSCC prognostic modeling, emphasizing radiotherapy sensitivity and integrating immune and therapeutic dimensions. The resulting model offers a novel approach to improve prognostic accuracy and guide treatment strategies for HNSCC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.